Trxade Group (MEDS) just unveiled an update.
TRxADE Health, Inc. is facing compliance issues after failing to submit its required quarterly financial report on time, receiving a notice from Nasdaq that it must propose a compliance plan by July 22, 2024. Despite the delay having no immediate effect on its stock trading, the company’s ability to maintain its listing could be jeopardized if further delays occur. Additionally, the board has strengthened with the appointment of Mayur Doshi and Narasimhan Mani, two professionals with extensive experience in the pharmaceutical industry, while directors Jeff Newell and Michael L. Peterson have resigned without dispute.
For an in-depth examination of MEDS stock, go to TipRanks’ Stock Analysis page.
